External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

(Bloomberg) -- Johnson & Johnson is considering a sale of its anti-dandruff shampoo Nizoral as the U.S. health-care giant continues to streamline its portfolio of products, according to people familiar with the matter.

A sale of Nizoral could be valued at a few hundred million dollars and attract other health-care and consumer companies with an interest in over-the-counter treatments, the people said, asking not to be identified because the deliberations are private. J&J is working with financial advisers on the sale, which is at a preliminary stage, the people said.

A spokesman for J&J declined to comment.

J&J has been reviewing products ranging from its over-the-counter business to medical devices. Earlier this year, it agreed to sell its blister and lip-care treatment Compeed to HRA Pharma. It’s also considering a divestiture of its vaginal-mesh surgical product, which could fetch from $500 million to $1 billion, people familiar with the matter have said. J&J is also evaluating options for the diabetes-care business, including a sale, partnership or joint venture.

While the health-care conglomerate has major medical-device and consumer divisions, drugs have been a recent standout. That’s helped J&J outpace many of its large pharmaceutical rivals this year. After buying Actelion Ltd. for $30 billion this year, Johnson & Johnson has signaled that a new generation of medicines holds the key to its future profits as some of its best-selling drugs begin to lose dominance.

--With assistance from Jared S. Hopkins

To contact the reporter on this story: Manuel Baigorri in London at mbaigorri@bloomberg.net.

To contact the editors responsible for this story: Dinesh Nair at dnair5@bloomberg.net, John J. Edwards III

©2017 Bloomberg L.P.

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

Bloomberg